Catalyst Wire Dossier Catalyst Wire Dossier

Semaxanib

SU5416 · Sugen, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Semaxanib, covering 2013-01-23 to 2018-06-27. Get the full timeline:

Most recent: Clinical Trial Update: SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy [Phase 1, Phase 2]

See pricing